Chimeric Therapeutics Limited
Chimeric Therapeutics Limited
Your view on CHM.AX
Overview
What the company does, where it operates, and who runs it.
About Chimeric Therapeutics Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Rebecca McQualter
- Headquarters
- 62 Lygon Street, Carlton, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Rebecca McQualter
- Headquarters
- 62 Lygon Street, Carlton, VIC, AU
Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical firm dedicated to developing and commercializing a diverse array of cell therapies designed to combat various cancers.
Its lead natural killer (NK) cell platform, CHM 0201, is currently undergoing Phase I clinical evaluation for both solid tumors and hematological malignancies. Another key candidate, CHM 1101 (a CLTX CAR T therapy), is also in Phase I trials, specifically targeting recurrent or progressive glioblastoma in patients expressing MMP2+.
Beyond these, the company's development pipeline encompasses CHM 0301 for blood cancers; CLTX CAR NK (CHM 1301) and CDH17 CAR NK (CHM 2301) for solid tumors.
The CLTX CAR T platform (CHM 1101) is additionally being investigated for melanoma, colorectal, and prostate cancers, while CDH17 CAR T (CHM 2101) is being developed for neuroendocrine, colorectal, pancreatic, and gastric cancers. Chimeric Therapeutics, headquartered in Carlton, Australia, was founded in 2020.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Chimeric Therapeutics Limited. Starting points for Chimeric Therapeutics Limited: EPS -AUD 1.50, beta 0.74 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Chimeric Therapeutics Limited. Chimeric Therapeutics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Chimeric Therapeutics Limited. Trailing twelve-month EPS for Chimeric Therapeutics Limited stands at -AUD 1.50. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Earnings Estimate
| EPS | Current YearFY Jun 2027 |
|---|---|
| Avg. estimate | AUD 0.00 |
| Low estimate | AUD 0.00 |
| High estimate | AUD 0.00 |
| No. of analysts | 0 |
| Year-ago EPS | −AUD 0.61 |
| Growth | +100.0% |
Revenue Estimate
| Revenue | Current YearFY Jun 2027 |
|---|---|
| Avg. estimate | AUD 480.58M |
| Low estimate | AUD 480.58M |
| High estimate | AUD 480.58M |
| No. of analysts | 1 |
| Year-ago revenue | AUD 0.00 |
| Growth | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 20, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Chimeric Therapeutics Limited. Chimeric Therapeutics Limited has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| 1AD.AXAdAlta Limited | Healthcare | Biotechnology | — | ||
| ACR.AXAcrux Limited | Healthcare | Biotechnology | — | ||
| BGT.AXBio-Gene Technology Limited | Basic Materials | Agricultural Inputs | — | ||
| BIT.AXBiotron Limited | Healthcare | Biotechnology | — | ||
| CAN.AXCann Group Limited | Healthcare | Drug Manufacturers - Specialty & Generic | — | ||
| ECS.AXECS Botanics Holdings Ltd | Healthcare | Drug Manufacturers - Specialty & Generic | — | ||
| HIQ.AXHITIQ Limited | Healthcare | Medical - Healthcare Information Services | — | ||
| IXC.AXInvex Therapeutics Ltd | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PHYOFIXICO plc | Healthcare | OTC | $6.5M | ||
| PKTXProtoKinetix, Incorporated | Healthcare | OTC | $2.7M | ||
| PLRXPliant Therapeutics, Inc. | Healthcare | NASDAQ | $41.0M | ||
| PLRZPolyrizon Ltd. | Healthcare | NASDAQ | $12.4M | ||
| PLURPluri Inc. | Healthcare | NASDAQ | $9.9M | ||
| PLXProtalix BioTherapeutics, Inc. | Healthcare | AMEX | $254.6M | ||
| PLYXPolaryx Therapeutics, Inc. Common Stock | Healthcare | NASDAQ | $80.3M | ||
| PMCBPharmaCyte Biotech, Inc. | Healthcare | NASDAQ | $3.0M | ||
| PMNProMIS Neurosciences, Inc. | Healthcare | NASDAQ | $28.2M | ||
| PMVPPMV Pharmaceuticals, Inc. | Healthcare | NASDAQ | $65.1M | ||
| POLBFPoolbeg Pharma PLC | Healthcare | OTC | $46.6M | ||
| PPBTPurple Biotech Ltd. | Healthcare | NASDAQ | $236,124 | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Chimeric Therapeutics Limited. Coverage tracks Chimeric Therapeutics Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Chimeric Therapeutics Limited.